Holen Sie sich die Stockscreener-App
489.01
0.82%
3.97
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TMO?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$485.04
Offen:
$486.73
24-Stunden-Volumen:
2.46M
Relative Volume:
0.92
Marktkapitalisierung:
$184.66B
Einnahmen:
$43.21B
Nettoeinkommen (Verlust:
$6.58B
KGV:
28.28
EPS:
17.29
Netto-Cashflow:
$6.17B
1W Leistung:
+6.14%
1M Leistung:
+16.99%
6M Leistung:
-8.05%
1J Leistung:
-19.00%
1-Tages-Spanne:
$486.00
$491.55
1-Wochen-Bereich:
$459.33
$491.55
52-Wochen-Spanne:
$385.46
$627.88
Thermo Fisher Scientific Inc Stock (TMO) Company Profile
Firmenname
Thermo Fisher Scientific Inc
Sektor
Branche
Telefon
(781) 622-1000
Adresse
168 THIRD AVENUE, WALTHAM, MA
Vergleichen Sie TMO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TMO
Thermo Fisher Scientific Inc
|
489.01 | 183.16B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
210.93 | 150.53B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
650.84 | 52.32B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
119.20 | 33.77B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
191.09 | 32.20B | 15.50B | 1.33B | 2.16B | 7.34 |
Thermo Fisher Scientific Inc Stock (TMO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-24 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-07-11 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2025-07-09 | Herabstufung | UBS | Buy → Neutral |
| 2025-01-10 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2024-12-23 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-10-14 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-10-01 | Eingeleitet | Stephens | Overweight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Overweight |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-03-18 | Fortgesetzt | Citigroup | Neutral |
| 2024-01-24 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-01-08 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2023-12-18 | Eingeleitet | HSBC Securities | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-10-26 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-10-25 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2023-09-28 | Eingeleitet | Bernstein | Outperform |
| 2023-09-06 | Fortgesetzt | Citigroup | Buy |
| 2023-07-19 | Eingeleitet | Raymond James | Outperform |
| 2023-07-19 | Bestätigt | Robert W. Baird | Outperform |
| 2023-07-13 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2023-04-04 | Bestätigt | Barclays | Overweight |
| 2022-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-10-27 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2022-08-25 | Eingeleitet | Credit Suisse | Neutral |
| 2022-04-25 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2022-01-26 | Fortgesetzt | Barclays | Overweight |
| 2021-10-20 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-07-16 | Eingeleitet | The Benchmark Company | Buy |
| 2021-03-18 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-03-03 | Eingeleitet | Barclays | Overweight |
| 2021-01-08 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-12-02 | Eingeleitet | Goldman | Buy |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2020-09-30 | Eingeleitet | Atlantic Equities | Overweight |
| 2020-09-14 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-08-20 | Fortgesetzt | JP Morgan | Overweight |
| 2020-07-15 | Hochstufung | Cleveland Research | Neutral → Buy |
| 2020-07-07 | Bestätigt | Needham | Buy |
| 2020-04-23 | Bestätigt | Needham | Buy |
| 2020-01-31 | Bestätigt | Needham | Buy |
| 2020-01-22 | Eingeleitet | Credit Suisse | Neutral |
| 2020-01-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-11-15 | Eingeleitet | Stifel | Buy |
| 2019-07-25 | Bestätigt | Needham | Buy |
| 2019-07-16 | Herabstufung | Needham | Strong Buy → Buy |
| 2019-05-30 | Eingeleitet | Wolfe Research | Outperform |
| 2019-05-23 | Bestätigt | Needham | Strong Buy |
| 2019-04-22 | Bestätigt | Needham | Strong Buy |
| 2019-04-16 | Bestätigt | BofA/Merrill | Buy |
Alle ansehen
Thermo Fisher Scientific Inc Aktie (TMO) Neueste Nachrichten
Day 7 of Gains Streak for Thermo Fisher Scientific Stock with 8.9% Return (vs. -5.8% YTD) [8/15/2025] - Trefis
Is Thermo Fisher Scientific Inc.’s growth already priced inPortfolio Risk Summary & Expert Curated Trade Ideas - thegnnews.com
Is Now a Good Time to Reenter Thermo Fisher Scientific Inc.2025 Winners & Losers & Reliable Price Action Trade Plans - beatles.ru
Epigenetics Market worth US$4.29 billion in 2030 with 13.9% CAGR | MarketsandMarkets™ - PR Newswire UK
Digital health companies list reveals industry leaders and newcomers in Silicon Valley - The Business Journals
Thermo Fisher Navigates 92nd in $940M Volume Amid FDA Approval and Sanofi Strategic Expansion - AInvest
Syncell and Thermo Fisher Collaborate on High-Resolution Spatial Proteomics Workflow - AInvest
Taiwan's Syncell partners with Thermo Fisher to advance high-resolution spatial proteomics - BioSpectrum Asia
Thermo Fisher teams up with Syncell for spatial proteomics integration - Yahoo Finance
HIV Diagnostics Company Evaluation Report 2025 | Abbott, Siemens Healthineers, and Thermo Fisher Scientific Lead the Market with Innovative Portfolios and Strategic Expansion - Yahoo Finance
Recombinant DNA Technology Market Trends, Dynamic Innovation, - openPR.com
Here's How Much a $1000 Investment in Thermo Fisher Scientific Made 10 Years Ago Would Be Worth Today - Yahoo Finance
Toast, Amazon, Thermo Fisher Scientific And An Industrial Stock On CNBC's 'Final Trades' - Benzinga
Syncell Announces Strategic Co-Marketing Agreement to Advance High-Resolution Spatial Proteomics - Business Wire
Major biopharma firm sells Sunnyvale building in real estate consolidation - The Business Journals
Saudi Arabia Clinical Chemistry Analyzer Market Forecast and Company Analysis Report 2025-2033 Featuring Thermo Fisher Scientific, Abbott, Siemens, Danaher, J&J, Sysmex ADR, HORIBA, Hitachi - GlobeNewswire
Mexico Microcarrier Market Trends and Company Analysis Report 2025-2033 Featuring BD, Thermo Fisher Scientific, Merck, Eppendorf, Danaher, Sartorius, Bio Rad, Corning, Lonza Group, Getinge - Yahoo Finance
Clinical Microbiology Market to Reach $6.9 Billion by 2029, Driven by Advanced Diagnostics and Regulatory Demand | MarketsandMarkets™. - GlobeNewswire Inc.
Apoptosis Market Future Business Opportunities 2025-2032 | - openPR.com
Heron Therapeutics enters supply agreement with Patheon and Thermo Fisher - Investing.com Nigeria
Thermo Fisher Scientific (TMO) Oncomine Dx Test Gains FDA Approval for NSCLC Treatment - simplywall.st
FDA approves Thermo Fisher’s diagnostic test for new NSCLC treatment - Medical Device Network
US Durable Medical Equipment Market Forecast and Competitive Landscape Report 2025-2033 | Invacare, NOVA, Inogen, Thermo Fisher Scientific, Abbott, Medtronic, Baxter, B. Braun, Boston Scientific, BD - Yahoo Finance
Becton, Dickinson shares rise 1.26% premarket after Thermo Fisher Scientific gets US FDA approval for lung cancer test. - AInvest
Thermo Fisher Scientific: A Premium Growth Story at a Discount Valuation - AInvest
Thermo Fisher: Growth Acceleration And Margin Expansion Should Drive The Upside - Seeking Alpha
Thermo Fisher's Stock Climbs 0.36% on FDA Diagnostic Approval Surges to 119th in Activity with $790M Volume - AInvest
Thermo Fisher Receives FDA Approval for NGS-Based Companion Diagnostic for New Non-Small Cell Lung Cancer Treatment - Business Wire
Microplate Readers Market Growth and Future Scope 2025-2032 | - openPR.com
Thermo Fisher Scientific – Environmental and Process Monitoring Instruments : Quotes, Address, Contact - AZoMining
Do Tariffs and Buyback Completion Signal a New Strategic Phase for Thermo Fisher (TMO)? - simplywall.st
Thermo Fisher Scientific Inc.'s (NYSE:TMO) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum? - 富途牛牛
Thermo Fisher Scientific: A Deep-Value Buy in a Misunderstood Sector - AInvest
Thermo Fisher Stock Set for Further Re-rating as Market Finds Correct Valuation - AInvest
Thermo Fisher: The Rerating Is Just Getting StartedBuy (NYSE:TMO) - Seeking Alpha
Thermo Fisher Scientific Stock (TMO) Opinions on $2 Billion Investment Plan - Quiver Quantitative
Fund Update: FLOSSBACH VON STORCH SE added 1,314,182 shares of THERMO FISHER SCIENTIFIC ($TMO) to their portfolio - Quiver Quantitative
U.S. Active Pharmaceutical Ingredients CDMO Market Report 2025-2030 | Competitive Analysis of Thermo Fisher Scientific, Novo Group, Cambrex, Piramal, Corden, Siegfried, Seqens, SK, Noramco, BSP - GlobeNewswire
Thermo Fisher shells out $97m to expand clinical research labs - BioXconomy
Thermo Fisher Tumbles 3.75% on $1.15B Volume Ranks 72nd in Market Activity Amid Mixed Q2 Results and Revised Guidance - AInvest
Thermo Fisher Unveils Next-Gen Electron Microscopes for Enhanced Lab Efficiency - Lab Manager
Thermo Fisher Q2: Pharma And Biotech Gains Offset By Weak Academic And Gov't Markets (TMO) - Seeking Alpha
Fund Update: PARNASSUS INVESTMENTS, LLC added 744,827 shares of THERMO FISHER SCIENTIFIC ($TMO) to their portfolio - Quiver Quantitative
Cell Line Development Market Outlook Report 2025-2034: - GlobeNewswire
Cell Line Development Market Outlook Report 2025-2034: PromoCell, Novartis, Genscript Biotech, Sartorius, and Thermo Fisher Scientific Dominate the Industry - Yahoo Finance
Thermo Fisher launches two microscopes - Scientist Live
Drug Screening Market Is Booming So Rapidly 2025-2032 -Thermo - openPR.com
Kovitz Core Equity Strategy Boosts Position in Thermo Fisher Scientific Amidst Tariff Uncertainty - AInvest
Here’s Why Kovitz Core Equity Strategy Increased Its Position in Thermo Fisher Scientific (TMO) - Insider Monkey
Proteomics Market Top PlayersThermo Fisher Scientific, Inc. - openPR.com
Thermo Fisher Scientific Falls 0.03% as $920M Volume Ranks 93rd on Strong Institutional Buying and Upgraded Analyst Targets - AInvest
Finanzdaten der Thermo Fisher Scientific Inc-Aktie (TMO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.34%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):